Back to Journals » Journal of Asthma and Allergy » Volume 6

A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhinoconjunctivitis: a randomized, double-blind, placebo-controlled study

Authors Lukat K, Rivas P, Roger A, Kowalski ML, Botzen U, Wessel F, Sanquer F, Agache I, Izquierdo I

Received 23 October 2012

Accepted for publication 6 December 2012

Published 22 February 2013 Volume 2013:6 Pages 31—39

DOI https://doi.org/10.2147/JAA.S39496

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


KF Lukat,1 P Rivas,2 A Roger,3 ML Kowalski,4 U Botzen,5 F Wessel,6 F Sanquer,7 I Agache,8 I Izquierdo9

Investigators working group clinical trial

1Institute Respiratory Science, Dusseldorf, Germany; 2Hospital Viladecans, ENT Department, Barcelona, Spain; 3Hospital Universitario “German Trias i Pujol,” Badalona, Spain; 4Medical University of Lodz, Immunology, Rheumatology, and Allergy, Lodz, Poland; 5ENT, private consult, Solingen, Germany; 6Allergologist, Private Practice, Nantes, France; 7Allergologist, Private Practice, Bordeaux, France; 8Medical Clinical SC Radoi Mariana SRL, Brasov, Romania; 9Clinical Research and Development, J Uriach y Compañia, SA Barcelona, Spain

Background: H1-antihistamines are recommended as the first-line symptomatic treatment of allergic rhinitis. The objective of this study was to evaluate the effects of rupatadine (RUP) versus desloratadine (DES) in subjects with seasonal allergic rhinitis (SAR).
Method: To assess the efficacy and safety of RUP in SAR in comparison with placebo (PL) and DES. A randomized, double-blind, multicenter, international, and PL-controlled study was carried out. The main selection criteria included SAR patients over 12 years old with a positive prick test to a relevant seasonal allergen for the geographic area. Symptomatic patients at screening with a nasal symptom sum score of ≥6 points (nasal discharge, nasal obstruction, sneezing, and nasal pruritus), a non-nasal score of ≥3 points (ocular pruritus, ocular redness, and tearing eyes), and a rhinorrhea score of ≥2 points with laboratory test results and electrocardiography within acceptable limits were included in the study. Change from baseline in the total symptom-score (T7SS) over the 4-week treatment period (reflective evaluation) was considered the primary efficacy variable. Secondary efficacy measures included total nasal symptom score (T4NSS) and conjunctival symptom score (T3NNSS), both of which are reflective and instantaneous evaluations. Furthermore questions related to quality of life (eg, sleep disturbances or impairment of daily activities) have also been evaluated. Safety was assessed according to adverse events reported, as well as laboratory and electrocardiography controls.
Results: A total of 379 patients were randomized, of which 356 were included and allocated to PL (n = 122), RUP (n = 117), or DES (n = 117). Mean change of T7SS over the 4-week treatment period was significantly reduced in the RUP (−46.1%, P = 0.03) and DES (−48.9%, P = 0.01) groups, compared with PL. Similarly, RUP and DES were comparable and significantly superior to PL for all secondary endpoints, including nasal and conjunctival symptoms and patients’ and investigator’s overall clinical opinions. Symptom score evaluation (both reflective and instantaneous evaluations) throughout the treatment period showed a progressive and maintained significant improvement with both treatments at day 7 (P = 0.01), day 14 (P = 0.007), and day 21 (P = 0.01) in comparison with PL. Adverse events were scarce and were similar in both treatment groups. Electrocardiography (QTc) and lab test results did not show any relevant findings.
Conclusion: RUP is a very good choice for SAR due to its contribution to the improvement of nasal (including obstruction) and non-nasal symptoms to a similar degree as DES.

Keywords: allergic rhinitis, seasonal, H1-antihistamines, rupatadine, desloratadine

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]